ACTRIMS Investor Call

Sanofi was pleased to invite investors and analysts to participate in a live webcast discussing tolebrutinib data presented during the ACTRIMS scientific program (February 24-26,2022).

(16h00 CET / 10:00am EST)

Avec

Dietmar Berger

Dietmar Berger

Global Head of Development,

Tom Snow

Tom Snow

Global Franchise Head, Neurology

Erik Wallstroem

Erik Wallstroem

Therapeutic Area Head, Multiple Sclerosis

Anthony Traboulsee

Anthony Traboulsee

Professor and Research Chair of the MS Society of Canada at the University of British Columbia,Vancouver

Tim Turner

Tim Turner

Global Project Head, Neurology

Documents à télécharger

Prospectus AMF

Présentation (en anglais)

Tolebrutinib_Outcomes of COVID-19 Cases from LTE Study in MS

Tolebrutinib_18-month Results from the LTE Study in MS